Presence of HCV RNA in peripheral blood mononuclear cells may predict patients' response to interferon and ribavirin therapy

Presence of HCV RNA in peripheral blood mononuclear cells may predict patients' response to interferon and ribavirin therapy

BACKGROUND AND OBJECTIVES: Hepatitis C virus (HCV) is considered a hepatotropic virus, but it can replicate in peripheral blood mononuclear cells (PBMCs), which influence the sustained virological response (SVR) of the patients, as well as relapse in successfully treated patients. The main objective...

Full description

Bibliographic Details
Main Authors:	Nasib Zaman, Muhammad Javaid Asad, Abida Raza, Ghazala Kaukab Raja, Shamim Akhter, Majid Mahmood, Raja Tahir Mahmood
Format:	Article
Language:	English
Published:	King Faisal Specialist Hospital and Research Centre 2014-09-01
Series:	Annals of Saudi Medicine
Online Access:	https://www.annsaudimed.net/doi/full/10.5144/0256-4947.2014.401

Similar Items

Suppression of ribosomal protein synthesis and protein translation factors by Peg-interferon alpha/ribavirin in HCV patients blood mononuclear cells (PBMC)
by: Gupta Rahul, et al.
Published: (2012-03-01)

Efficacy Of Pegylated Interferon And Ribavirin Treatment In Coinfected HIV HCV Patients
by: Dumitru Irina Magdalena, et al.
Published: (2017-02-01)

Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
by: Janine Hartl, et al.
Published: (2012-07-01)

Increase of ribavirin dose improves sustained virological response in HCV-genotype 1 patients with a partial response to peg-interferon and ribavirin
by: Fabio Conti, et al.
Published: (2014-03-01)

Genetic Variability of Hepatitis C Virus (HCV) 5' Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and Ribavirin.
by: Iwona Bukowska-Ośko, et al.
Published: (2015-01-01)

PEG-Interferon-α ribavirin-induced HCV viral clearance: a pharmacogenetic multicenter Spanish study
by: Javier Milara, et al.
Published: (2015-01-01)

Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
by: Juan Macías, et al.
Published: (2015-01-01)

Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection
by: Mario Peribañez-Gonzalez, et al.
Published: (2013-03-01)

Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.
by: Helen Kovari, et al.
Published: (2015-01-01)

Replication of hepatitis C virus in peripheral blood mononuclear cells in patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin
by: Malgorzata Inglot, et al.
Published: (2013-03-01)

Analysis of Genotype 1b Hepatitis C Virus IRES in Serum and Peripheral Blood Mononuclear Cells in Patients Treated with Interferon and Ribavirin
by: Iwona Bukowska-Ośko, et al.
Published: (2014-01-01)

Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patients.
by: Antonio Rivero-Juárez, et al.
Published: (2012-01-01)

Effects of Pegylated Interferon Alpha and Ribavirin (pegIFN-α/RBV) Therapeutic Approach on Regulatory T Cells in HCV-Monoinfected and HCV/HIV-Coinfected Patients
by: Kamil Grubczak, et al.
Published: (2021-07-01)

ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection.
by: Tarik Asselah, et al.
Published: (2015-01-01)

The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive individuals
by: Vogel M, et al.
Published: (2010-03-01)

Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials
by: Donald M. Jensen, et al.
Published: (2016-05-01)

Effects of ribavirin on cytokine production of recall antigens and phytohemaglutinin-stimulated peripheral blood mononuclear cells. (Inhibitory effects of ribavirin on cytokine production)
by: Silvia Sookoian, et al.
Published: (2004-07-01)

Interferon and ribavirin combination treatment synergistically inhibit HCV internal ribosome entry site mediated translation at the level of polyribosome formation.
by: Rajesh Panigrahi, et al.
Published: (2013-01-01)

Analysis of ineffective antiviral therapy with pegylated interferon and ribavirin in a patient with chronic hepatitis C infected with HCV genotype 2
by: O O Znoyko, et al.
Published: (2016-05-01)

Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors.
by: Nicola Coppola, et al.
Published: (2014-01-01)

Favorable Outcomes of Chinese HCV-Related Cirrhotic Patients with Sustained Virological Response after Pegylated Interferon Plus Ribavirin Treatment
by: Geng-lin Zhang, et al.
Published: (2017-01-01)

Pegylated interferon may be considered in chronic viral hepatitis E resistant to ribavirin in kidney transplant recipients
by: I. Ollivier-Hourmand, et al.
Published: (2020-07-01)

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
by: Gonçales Neiva SL, et al.
Published: (2010-07-01)

Induction with ribavirin in a relapsing patient with chronic HCV hepatitis
by: Claudio Ucciferri, et al.
Published: (2012-05-01)

Individualizing HCV treatment with peginterferon and ribavirin: what needs to be done?
by: Donald M. Jensen
Published: (2009-01-01)

Induction with ribavirin in a relapsing patient with chronic HCV hepatitis
by: Claudio Ucciferri, et al.

Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin
by: Guillermo Cabrera Álvarez, et al.
Published: (2011-10-01)

Longitudinal study of a human drug-induced model of autoantibody to cytoplasmic rods/rings following HCV therapy with ribavirin and interferon-α.
by: Gerson Dierley Keppeke, et al.
Published: (2012-01-01)

Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients.
by: Giulia Marchetti, et al.
Published: (2012-01-01)

Association of baseline CD4+ cell count and HIV-RNA on sustained virologic response to interferon-ribavirin in HIV/HCV coinfected patients
by: Teresa Aldámiz-Echevarría, et al.
Published: (2015-07-01)

Comparison study between the treatment of Hepatitis C virus with (peg-interferon, ribavirin, silymarin) and (peg-interferon, ribavirin) in Baghdad teaching hospital.
by: Khalid A. Al-Khazraji
Published: (2017-04-01)

Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
by: Saleem Sana, et al.
Published: (2011-05-01)

Characteristics of hepatitis C treatment with pegylated interferons and ribavirin
by: Ricardo Jiménez-Méndez, et al.
Published: (2010-01-01)

The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin
by: K.S. Abdelkawy, et al.
Published: (2020-01-01)

Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients.
by: Montserrat de Castellarnau, et al.
Published: (2012-01-01)

Pegylated interferon, ribavirin, and frequent supportive therapy with growth factors. Which pathogenesis for a severe psoriasis complicating the treatment of chronic HCV hepatitis?
by: Roberto Manfredi
Published: (2009-12-01)

IFI35, mir-99a and HCV genotype to predict sustained virological response to pegylated-interferon plus ribavirin in chronic hepatitis C.
by: Emilie Estrabaud, et al.
Published: (2015-01-01)

Severe psoriasis emerged after treatment of chronic HCV co-infection with pegylated-interferon and ribavirin, supported by neutropenia rescue with repeated filgrastim administration
by: Sabbatani Sergio, et al.
Published: (2010-05-01)

Somatic pain associated with initiation of interferon-alpha (IFN-α) plus ribavirin (RBV) therapy in chronic HCV patients: A prospective study
by: Chih Ying Lin, et al.
Published: (2020-02-01)

Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection
by: Cody Orr, et al.
Published: (2020-12-01)